Kane Biotech Inc. KNE.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.90K | 31.50K | -15.20K | 6.20K | 20.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.90K | 31.50K | -15.20K | 6.20K | 20.20K |
| Cost of Revenue | 4.80K | 34.30K | -20.60K | 9.90K | 53.10K |
| Gross Profit | 1.00K | -2.80K | 5.40K | -3.70K | -32.90K |
| SG&A Expenses | 485.40K | 335.80K | 374.50K | 274.90K | 101.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 572.70K | 522.30K | 436.40K | 400.70K | 219.30K |
| Operating Income | -566.80K | -490.80K | -451.50K | -394.60K | -199.10K |
| Income Before Tax | -599.50K | -518.00K | -469.70K | -441.00K | -251.90K |
| Income Tax Expenses | 2.80K | 3.10K | -77.50K | -- | -- |
| Earnings from Continuing Operations | -602.30K | -521.10K | -392.30K | -441.00K | -251.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -602.30K | -521.10K | -392.30K | -441.00K | -251.90K |
| EBIT | -566.80K | -490.80K | -451.50K | -394.60K | -199.10K |
| EBITDA | -557.30K | -477.00K | -440.50K | -323.80K | -165.60K |
| EPS Basic | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 83.36M | 181.86M | 181.60M | 339.16M | 156.70M |
| Average Diluted Shares Outstanding | 83.36M | 181.86M | 181.60M | 339.16M | 156.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |